CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.34B
This Quarter Return
+7.66%
1 Year Return
+85.27%
3 Year Return
+2,244.39%
5 Year Return
+2,846.94%
10 Year Return
+51,155.97%
AUM
$373M
AUM Growth
+$373M
(-14%)
Cap. Flow
-$46.3M
Cap. Flow
% of AUM
-12.42%
Top 10 Holdings %
Top 10 Hldgs %
44.78%
Holding
63
New
17
Increased
9
Reduced
13
Closed
10
Top Buys
| 1 |
QCOR
QUESTCOR PHARMA INC
QCOR
|
$18.5M |
| 2 |
CELG
Celgene Corp
CELG
|
$17.2M |
| 3 |
Akebia Therapeutics
AKBA
|
$11.1M |
| 4 |
Omeros
OMER
|
$10.8M |
| 5 |
Heron Therapeutics
HRTX
|
$8.62M |
Top Sells
| 1 |
MDVN
MEDIVATION, INC.
MDVN
|
$38.6M |
| 2 |
CBST
CUBIST PHARMACEUTICALS INC
CBST
|
$21.9M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
$20.5M |
| 4 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
$16.5M |
| 5 |
IDIX
IDENIX PHARMACEUTICALS INC
IDIX
|
$15.1M |
Sector Composition
| 1 | Healthcare | 78.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
RCPT
1
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
| $20.4M | 5.41% | 478,800 +28,800 | +6% | +$1.23M |
|
|
2
Omeros
OMER
$283M
| $19.5M | 5.18% | 1,123,000 +623,000 | +125% | +$10.8M |
|
|
QCOR
3
DELISTED
QUESTCOR PHARMA INC
QCOR
| $18.5M | 4.9% | +200,000 | New | +$18.5M |
|
4
Karyopharm Therapeutics
KPTI
$61.7M
| $17.9M | 4.75% | 385,000 +105,000 | +38% | +$4.89M |
|
|
DYAX
5
DELISTED
DYAX CORPORATION
DYAX
| $17.3M | 4.58% | 1,800,000 -200,000 | -10% | -$1.92M |
|
|
CELG
6
DELISTED
Celgene Corp
CELG
| $17.2M | 4.55% | +200,000 | New | +$17.2M |
|
7
BioCryst Pharmaceuticals
BCRX
$1.74B
| $14.9M | 3.95% | 1,168,000 | – | – |
|
8
Jazz Pharmaceuticals
JAZZ
$7.75B
| $14.7M | 3.9% | 100,000 | – | – |
|
9
Puma Biotechnology
PBYI
$254M
| $13.7M | 3.63% | 207,500 | – | – |
|
10
Arrowhead Research
ARWR
$3.05B
| $12.9M | 3.41% | 900,000 -100,000 | -10% | -$1.43M |
|
|
11
Akebia Therapeutics
AKBA
$833M
| $11.1M | 2.95% | +400,000 | New | +$11.1M |
|
12
Galectin Therapeutics
GALT
$274M
| $11M | 2.93% | 800,000 +452,000 | +130% | +$6.24M |
|
|
TSRO
13
DELISTED
TESARO, Inc.
TSRO
| $9.33M | 2.47% | 300,000 | – | – |
|
|
14
Heron Therapeutics
HRTX
$207M
| $8.62M | 2.29% | +700,000 | New | +$8.62M |
|
15
DexCom
DXCM
$29.5B
| $7.93M | 2.1% | 200,000 -100,000 | -33% | -$3.97M |
|
16
Sangamo Therapeutics
SGMO
$157M
| $7.64M | 2.02% | 500,000 -100,000 | -17% | -$1.53M |
|
|
MNK
17
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $7.2M | 1.91% | +90,000 | New | +$7.2M |
|
18
Talphera
TLPH
$11.1M
| $7.18M | 1.9% | 700,000 -50,000 | -7% | -$513K |
|
19
Novavax
NVAX
$1.21B
| $6.93M | 1.84% | 1,500,000 +500,000 | +50% | +$2.31M |
|
|
XLRN
20
DELISTED
Acceleron Pharma Inc.
XLRN
| $6.79M | 1.8% | +200,000 | New | +$6.79M |
|
|
SRNE
21
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $6.75M | 1.79% | 1,000,000 +300,000 | +43% | +$2.03M |
|
|
CMRX
22
DELISTED
Chimerix, Inc.
CMRX
| $6.58M | 1.74% | 300,000 | – | – |
|
|
PTLA
23
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $5.84M | 1.55% | 200,000 | – | – |
|
24
Merck
MRK
$210B
| $5.79M | 1.53% | 100,000 -100,000 | -50% | -$5.79M |
|
|
EGRX
25
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $5.73M | 1.52% | 400,000 | – | – |
|